{{Rsnum
|rsid=2550948
|Chromosome=5
|position=1450329
|Orientation=minus
|GMAF=0.3567
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 31.0 | 49.6 | 19.5
| HCB | 4.4 | 21.9 | 73.7
| JPT | 1.8 | 17.7 | 80.5
| YRI | 2.7 | 28.6 | 68.7
| ASW | 7.0 | 35.1 | 57.9
| CHB | 4.4 | 21.9 | 73.7
| CHD | 0.9 | 29.4 | 69.7
| GIH | 16.8 | 46.5 | 36.6
| LWK | 0.0 | 29.1 | 70.9
| MEX | 17.2 | 46.6 | 36.2
| MKK | 2.6 | 30.8 | 66.7
| TSI | 35.3 | 51.0 | 13.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2550948
|Name_s=
|Gene_s=SLC6A3
|Feature=
|Evidence=PubMed ID:18802919
|Annotation=A study in 243 children with ADHD and their parents suggests a role for the promoter region of the SLC6A3 gene in ADHD susceptibility. In the DSM-IV combined subtype, results showed a preferential transmission of the haplotype A/C/C/C/A derived from five SNPs (rs2550948, rs11564750, rs261759, rs2652511, rs2975223) in 5' region of the SLC6A3 gene.
|Drugs=
|Drug Classes=
|Diseases=Attention Deficit Disorder with Hyperactivity
|Curation Level=Curated
|PharmGKB Accession ID=PA162355583
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2550948
|overall_frequency_n=51
|overall_frequency_d=128
|overall_frequency=0.398438
|n_genomes=33
|n_genomes_annotated=0
|n_haplomes=42
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}